NEW ORLEANS, LA—The use of intravascular imaging to guide complex PCI is associated with a significantly lower risk of target vessel failure when compared with conventional angiography, according to ...

Patients who underwent complex PCI for acute coronary syndrome followed by 3 months of dual-antiplatelet therapy (DAPT) with ticagrelor plus aspirin fared significantly better by dropping aspirin at ...

Please provide your email address to receive an email when new articles are posted on . In a non-prespecified analysis from the GLOBAL LEADERS study, a ticagrelor monotherapy regimen compared with a ...

Compared with other types of complex PCI, chronic total occlusion (CTO) PCI is less often associated with procedural success and carries a higher risk of complications such as coronary perforation and ...

It remains unknown whether the recent trend of short dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy can simply be applied to patients undergoing complex percutaneous coronary ...

Please provide your email address to receive an email when new articles are posted on . Among patients undergoing complex PCI with drug-eluting stents, a longer duration of dual antiplatelet therapy ...

PARIS — Long-term ticagrelor monotherapy after 1-month dual antiplatelet therapy (DAPT) may be a better option for patients undergoing complex percutaneous coronary intervention (PCI), suggests a new ...

Like TWILIGHT-DM, TWILIGHT-COMPLEX was also simultaneously published in the Journal of the American College of Cardiology. There were 2,620 people randomized to ticagrelor with or without aspirin ...

Optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI) leads to a larger minimum stent area but does not reduce the two-year rate of target vessel failure compared with ...

A first-of-its kind study using robotic technology to remotely control coronary guidewires and stents reported on the feasibility of performing percutaneous coronary intervention (PCI) on patients ...

In the TWILIGHT trial, switching from dual antiplatelet therapy (DAPT) with ticagrelor and aspirin to ticagrelor monotherapy at 3 months after percutaneous coronary intervention (PCI) was found to ...